Intravitreal Injection of Bevacizumab as Adjunctive Treatment for Proliferative Vitreoretinopathy

Objectives: To evaluate the midterm anatomical and functional outcomes of intravitreal injection bevacizumab in silicone oil–filled eyes as an adjunctive treatment for proliferative vitreoretinopathy. Material/patients and Method: The study included all 16 patients who underwent pars plana vitrectomy for treatment of proliferative vitreoretinopathy grade C or D, who received pars plana vitrectomy combined with silicone oil tamponade and intravitreal injection of 1.25mg bevacizumab at the end of surgery, and who were operated on by the same surgeon. Conclusions: This pilot study suggests that intravitreal injection of 1.25 mg bevacizumab as an adjunct to vitrectomy and silicone oil tamponade in treating proliferative vitreoretinopathy (grade C or D) appears to be effective and safe. Results: In all, 16 eyes from 16 patients were included in this study. Mean follow up time was 6.70 (SD = 2.07) months (range 3.0-10.0 months). The mean best-corrected visual acuity was 1.99 ± 0.327 log MAR at baseline, which improved to 0.82 ± 0.48 log MAR at the last visit (P < 0.001). Best-corrected visual acuity increased in 15 (93.7%) eyes and decreased in 1 (6.3%) eye atlast visit compared with baseline. 93.7 % of eyes had attached retina after SO removal in the end of study .